title: Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes.
abstract: BACKGROUND
  In India, refractive errors are a major cause of treatable blindness. Population surveys in southern India have shown prevalence of high myopia to be 4.32-4.54%. Photodynamic therapy (PDT) for choroidal neovascularization (CNV) caused by pathologic myopia is beneficial.
  
  
  OBJECTIVE
  To report the 24 months outcome of PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes.
  
  
  METHODS
  Prospective case series.
  
  
  METHODS
  Review of prospectively collected data of Indian patients with pathologic myopia and subfoveal CNV treated with verteporfin therapy between 2001 and 2005 using standard regimen for PDT.
  
  
  METHODS
  Wilcoxon signed rank test was used to see the difference in the mean letter acuity at intervals compared to baseline. Kaplan Meier Survival analysis was done to estimate the success rate of verteporfin therapy for CNV caused by pathologic myopia.
  
  
  RESULTS
  Fifteen patients (15 eyes) treated with standard fluence PDT and who had completed 24 months follow-up were analyzed. The mean spherical equivalent was -13.36 +/- 5.88 diopter. Five out of 15 eyes in six months, three out of 15 eyes at 12 months and four eyes out of 15 at 24 months had improved vision by > 10 letters. The mean number of treatment session was 2.2 in two years.
  
  
  CONCLUSIONS
  PDT with verteporfin for subfoveal CNV caused by pathologic myopia in Indian eyes is effective.
authors.affiliation: LV Prasad Eye Institute, Hyderabad, India. nazimul@rediffmail.com
authors.forename: Nazimul
authors.initials: N
authors.lastname: Hussain
authors.forename: Rohit
authors.initials: R
authors.lastname: Khanna
authors.forename: Taraprasad
authors.initials: T
authors.lastname: Das
authors.forename: Raja
authors.initials: R
authors.lastname: Narayanan
authors.forename: Oluleye Tunji
authors.initials: OT
authors.lastname: Sunday
authors.forename: Azad Gaurav
authors.initials: AG
authors.lastname: Bansal
authors.forename: Rajeev
authors.initials: R
authors.lastname: Reddy
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications* / Q000503:physiopathology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D019233:Retreatment; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin